% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Albers:303643,
      author       = {P. Albers$^*$ and T. Franiel and T. Kötter and G.
                      Kristiansen and K. Herrmann$^*$ and T. Wiegel},
      title        = {{T}he {E}arly {D}etection, {D}iagnostic {E}valuation, and
                      {L}ocal {T}reatment of {P}rostate {C}ancer: {A} {P}aradigm
                      {S}hift.},
      journal      = {Deutsches Ärzteblatt international},
      volume       = {122},
      number       = {15},
      issn         = {1866-0452},
      address      = {Köln},
      publisher    = {Dt. Ärzte-Verl.},
      reportid     = {DKFZ-2025-01707},
      pages        = {420-426},
      year         = {2025},
      note         = {#EA:C130# / 2025 Jul 5;122(15):420-426},
      abstract     = {Approximately 75 000 men receive a diagnosis of prostate
                      cancer in Germany each year. New data on the early
                      detection, diagnostic evaluation, and treatment of prostate
                      cancer provide the basis for a paradigm shift in the
                      management of locally confined prostate cancer.This
                      narrative review is based on the systematic literature
                      search that was carried out for the 2025 update of the
                      German clinical practice guideline on prostate
                      cancer.Risk-adapted early detection is now recommended. This
                      involves the measurement of a baseline PSA value at age 45
                      whose magnitude determines the interval of follow-up
                      testing: once every 5 years for baseline values below 1.5
                      ng/mL, and once every two years for baseline values between
                      1.5 and 3 ng/mL. Patients with PSA levels above 3 ng/mL
                      should undergo a repeat PSA test and, if these levels are
                      confirmed, receive a urological risk assessment including
                      prostatic volume, family history, and past medical history.
                      High risk patients should undergo magnetic resonance imaging
                      (MRI) and, if necessary, prostate biopsy. This new PSA-MRI
                      algorithm increases accuracy in detecting clinically
                      significant prostate cancers, enabling the previously
                      recommended annual testing and digital rectal examination to
                      be avoided. Another novelty is that the indication for an
                      active surveillance strategy for men with low-risk prostate
                      cancer has been expanded to ISUP grade group 1 and 2 cancers
                      with favorable risk.The need for high-quality diagnostic
                      testing, including MRI, with broad geographic coverage will
                      be a major challenge to the health care system, especially
                      with regard to accessibility. Patients can be expected to
                      benefit greatly from the new PSA-MRI algorithm, as it
                      eliminates unnecessary diagnostic testing and treatment
                      while enabling necessary treatment to be initiated earlier
                      and therefore with fewer side effects.},
      subtyp        = {Review Article},
      cin          = {C130 / ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)C130-20160331 / I:(DE-He78)ED01-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40536418},
      doi          = {10.3238/arztebl.m2025.0099},
      url          = {https://inrepo02.dkfz.de/record/303643},
}